NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE
Post# of 341
(Total Views: 161)
Posted On: 05/17/2022 3:58:22 PM
NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Participation in May 18 NYSE Trading Bell Ceremony
Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), will be participating in the morning trading bell ceremony at the New York Stock Exchange on May 18, 2022. The first psychedelics company to be listed on the NYSE, Cybin started trading on the exchange in August 2021. In addition, Cybin announced that management team members will be hosting in-person meetings with institutional investors in New York City on May 18–19. “We are delighted to be part of this ceremony as we celebrate the innovation that Cybin is bringing to the challenges of mental health treatments today,” said Cybin CEO Doug Drysdale in the press release. “As we progress from promising preclinical studies toward first-in-human trials, we are steadfastly committed to bringing improved therapeutic options to the millions of people who can benefit from our psychedelic-based therapies as quickly as possible.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), will be participating in the morning trading bell ceremony at the New York Stock Exchange on May 18, 2022. The first psychedelics company to be listed on the NYSE, Cybin started trading on the exchange in August 2021. In addition, Cybin announced that management team members will be hosting in-person meetings with institutional investors in New York City on May 18–19. “We are delighted to be part of this ceremony as we celebrate the innovation that Cybin is bringing to the challenges of mental health treatments today,” said Cybin CEO Doug Drysdale in the press release. “As we progress from promising preclinical studies toward first-in-human trials, we are steadfastly committed to bringing improved therapeutic options to the millions of people who can benefit from our psychedelic-based therapies as quickly as possible.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Cybin Inc (CYBN) Stock Research Links
Scroll down for more posts ▼